Kafayat Olushola Arowolo

Dr. Kafayat Olushola Arowolo

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2019 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
KAKafayat Olushola Arowolo
Kafayat Olushola Arowolo
CAChristianah Idowu Ayolabi
Christianah Idowu Ayolabi
BLBruna Lapinski
Bruna Lapinski
JSJucielia Stadinicki Santos
Jucielia Stadinicki Santos
SRSonia Mara Raboni
Sonia Mara Raboni

8 August 2020 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
KAKafayat Olushola Arowolo
Kafayat Olushola Arowolo
CAChristianah Ayolabi
Christianah Ayolabi
IAI. A. Adeleye
I. A. Adeleye
BLB. Lapinski
B. Lapinski
JSJ. S. Santos
J. S. Santos
SRSonia Mara Raboni
Sonia Mara Raboni

19 January 2026 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
PTPhionah Tushabe
Phionah Tushabe
MMManasi Majumdar
Manasi Majumdar
SCSarah Carlyle
Sarah Carlyle
LSLester Shulman
Lester Shulman
ASAlfred Ssekagiri
Alfred Ssekagiri
JBJosephine Bwogi
Josephine Bwogi
The novel oral poliovirus vaccine type 2 (nOPV2) was developed to reduce the risk of circulating vaccine-derived poliovirus outbreaks by incorporating genetic modifications to enhance genetic stability and reduce reversion to virulence while retaining protection. Here we report the characterization of 231 nOPV2 isolates from Uganda during a 1-year period following nOPV2 use. Whole-genome sequencing revealed that most isolates retained nOPV2’s genetic modifications, with limited mutations in the VP1 region indicating no relevant virus transmission. However, a double recombinant strain identified in a sewage sample lost all key nOPV2 modifications through recombination with enterovirus C strains upstream and downstream of the capsid coding region. This resulted in high neurovirulence comparable to that of wild-type 2 poliovirus. Despite this, the strain did not spread widely, probably due to high vaccination coverage. These findings underscore the enhanced genetic stability of nOPV2 and its reduced risk of reversion compared with Sabin monovalent OPV2 (mOPV2), while highlighting the importance of surveillance to detect rare recombination events. Continued use of nOPV2 and inactivated polio vaccine, combined with robust immunization and monitoring, remains essential for achieving and sustaining global polio eradication.

28 February 2023 in Viruses
Verified
Journal Article
Open access
PDF file
KAKafayat Olushola Arowolo
Kafayat Olushola Arowolo
CAChristianah I. Ayolabi
Christianah I. Ayolabi
IAIsaac A. Adeleye
Isaac A. Adeleye
BLBruna Lapinscki
Bruna Lapinscki
JSJucelia S. Santos
Jucelia S. Santos
SRSonia Mara Raboni
Sonia Mara Raboni
Norovirus (NoV) is a leading cause of viral gastroenteritis globally, especially in children below five years. Epidemiological studies on the diversity of NoV in middle- and low-income countries, including Nigeria, are limited. This study aimed to determine the genetic diversity of NoV in children below five years with acute gastroenteritis at three hospitals in Ogun State, Nigeria. A total of 331 fecal samples were collected from February 2015 to April 2017, while 175 were randomly selected and analyzed using RT-PCR, partial sequencing and phylogenetic analyses of both the polymerase (RdRp) and capsid (VP1) genes. NoV was detected in 5.1% (9/175; RdRp) and 2.3% (4/175; VP1) of samples, with 55.6% (5/9) co-infection with other enteric viruses. A diverse genotype distribution was identified, and GII.P4 was the dominant RdRp genotype detected (66.7%), with two genetic clusters, followed by GII.P31 (22.2%). The rare GII.P30 genotype (11.1%) was detected at a low rate for the first time in Nigeria. Based on the VP1 gene, GII.4 was the dominant genotype (75%), with two variants, Sydney 2012 and possibly New Orleans 2009, co-circulating during the study. Interestingly, both intergenotypic, GII.12(P4) and GII.4 New Orleans(P31), and intra-genotypic, GII.4 Sydney(P4) and GII.4 New Orleans(P4), putative recombinant strains were observed. This finding suggests the first likely report of GII.4 New Orleans(P31) in Nigeria. In addition, GII.12(P4) was first described in Africa and globally in this study, to the best of our knowledge. This study provided insights into the genetic diversity of NoV circulating in Nigeria, which would be useful for ongoing and future vaccine design and monitoring of emerging genotypes and recombinant strains.

27 November 2025 in Nature Microbiology
Verified
Journal Article
Open access
DCDarlan da Silva Candido
Darlan da Silva Candido
SDSimon Dellicour
Simon Dellicour
LCLaura V. Cooper
Laura V. Cooper
CPCarlos A. Prete
Carlos A. Prete
DJDavid Jorgensen
David Jorgensen
IBIsobel M. Blake
Isobel M. Blake
Outbreaks of vaccine-derived poliovirus type 2 (cVDPV2) have become a major threat to polio eradication. However, variations in spatiotemporal spread have not been quantified. Here we analysed cVDPV2 cases and wild poliovirus type 1 sequences to uncover spatiotemporal patterns and drivers of poliovirus spread. Between 1 May 2016 and 29 September 2023, 3,120 cVDPV2 poliomyelitis cases were reported across 75 outbreaks in 39 countries. Outbreaks had a median observed circulation of 202 (range 0–1,905) days and a median maximum distance of 231 (range 0–4,442) km. Wavefront velocity analysis of large outbreaks revealed a median velocity of spread of 2.3 (5th–95th percentile 0.7–9.2) km per day. International borders were associated with a slower velocity of spread ( P < 0.001), in periods with high estimated population immunity. Phylogeographic analysis of 1,572 global wild poliovirus 1 sequences revealed that historic spread resembles recent cVDPV2 patterns and that international spread is largely sustained by unidirectional movement between neighbouring countries. Our findings offer insights for enhancing the geographical scope of vaccination response in the final phases of poliovirus eradication.

23 June 2025
Verified
Preprint
Open access
PDF file
KAKafayat Olushola Arowolo
Kafayat Olushola Arowolo
DKDimitra Klapsa
Dimitra Klapsa
MMManasi Majumdar
Manasi Majumdar
EBErika Bujaki
Erika Bujaki
ATAlison Tedcastle
Alison Tedcastle
JMJavier Martin
Javier Martin
This protocol describes the amplification and whole-genome sequencing of poliovirus from clinical or environmental RNA extracts using an overlapping tiled amplicon strategy. Four overlapping PCR products are generated from viral RNA via RT-PCR. Amplicons are pooled and purified before library preparation for Oxford Nanopore or Illumina sequencing. This protocol enables robust recovery of full poliovirus genomes for surveillance and research purposes.